Intensity Therapeutics Bolsters Intellectual Property with New Patent Issuance in the U.S.

Overview of New Patent Issuance

In an important development on March 24, 2026, Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology firm dedicated to advancing cancer therapies, announced the issuance of a crucial new patent in the United States. This patent, numbered 12,496,345, is centered on innovative methods for treating cancer and enhances the company’s existing intellectual property (IP) portfolio, which includes protections in 41 countries around the world.

What This Patent Means

The new U.S. patent fortifies the credibility of Intensity's novel intratumoral technology, which has already shown promise in early clinical trials. Lewis H. Bender, the company’s founder and CEO, articulated that the patent's issuance confirms the innovative nature of their proprietary technology and expands their competitive edge. With four U.S. patents now secured and additional applications pending, Intensity is poised to protect and advance its therapeutic innovations against cancer.

The Strength of the IP Portfolio

Intensity’s robust intellectual property framework consists of 19 issued patents, featuring four patents granted in the U.S. The benefits of these patents extend beyond U.S. borders, allowing the company to enforce its claims in major pharmaceutical markets internationally. This expansive coverage ensures that Intensity stays ahead in the competitive landscape for cancer therapies. Key patents in their roster include:
1. U.S. Patent 9,351,997 - Method of treating cancer (registered May 31, 2016, expires December 6, 2033)
2. U.S. Patent 9,636,406 - Method of treating cancer (registered May 2, 2017, expires September 15, 2033)
3. U.S. Patent 10,888,618 - Method of treating cancer (registered January 12, 2021, expires September 15, 2033)
4. New U.S. Patent 12,496,345 - Method of treating cancer and an intratumoral formulation (registered December 16, 2025, expires September 15, 2033)

Understanding INT230-6

The newest patent supports INT230-6, Intensity's leading investigational product, which employs a unique formulation for direct intratumoral injections. This approach combines two effective anticancer agents—cisplatin and vinblastine sulfate—with a proprietary diffusion enhancer. This combination enhances the delivery of these drugs directly into tumors while maintaining safety.

The innovations associated with INT230-6 offer a groundbreaking alternative in cancer treatment by promoting not only localized tumor destruction but also engaging the body’s immune response in fighting the disease. This dual action is significant as it avoids the immunosuppressive effects typically seen with systemic chemotherapy.

Clinical Trials and Future Directions

Intensity has made significant strides in clinical research, having completed two studies with over 200 patients. These include a Phase 1/2 dose escalation study into metastatic cancers and a Phase 2 randomized trial focused on locally advanced breast cancer. Currently, further investigations, such as the Phase 3 INVINCIBLE-3 Study for soft tissue sarcomas, are underway, which centers around the long-term effectiveness and safety of INT230-6.

In partnership with esteemed research organizations, Intensity is committed to continuing its innovative approaches to cancer therapies and aims to significantly change the cancer treatment paradigm, potentially transforming fatal diseases into manageable conditions.

Conclusion

Overall, the latest patent issuance underlines Intensity Therapeutics' commitment to pioneering advancements in cancer treatments. By securing its strong IP portfolio, the company not only safeguards its innovative technologies but also establishes a solid foundation for future endeavors in the fight against cancer. For ongoing updates, follow Intensity Therapeutics’ journey on their official website and through their investor relations communications.